Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaboration with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI) marketplace research is delivering robust returns since inception. To name a couple winners, Nektar Therapeutics and Spectrum Pharmaceuticals delivered profits of 446% and 196% for our subscribers, respectively. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios. Of note, we’ll increase our price soon (SUBSCRIBE to IBI now to lock in the current price and save money). Click the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs. To read the FREE once-weekly articles covering promising small-cap bioscience firms, check out www.drtranbiosci.com (and make sure to register for our mailing list). You can read up on Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html "Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
Author of Quantitative Risk & Value and two 4-star books, designer of the systemic market risk indicator MTS10.
Fred is an individual investor with a professional and scientific mindset. He gained extensive skills in software design, information systems, consulting, marketing, in various environments: nuclear industry, banking, hospitals, manufacturing, distribution, public agencies. He has a PhD in computer science, an MSc in software engineering and an MSc in civil engineering.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Investor/Trader in biotech and tech sectors for 10 years. Founder & Editor of ROTY (Runners of the Year), a strategy and now Marketplace Service focused on discovering opportunities to achieve high % gains within a year´s time frame.
Importantly, I often highlight risk management and entry/exit strategies, as I believe they represent areas that are often neglected but materially important for readers to understand and apply if they want to be profitable long term.
President of Almington Capital - Merchant Bankers.
Investing in publicly traded securities, private equity, real estate, venture capital.
Taking advantage of deep value opportunities, growth opportunities, and special situations across a range of asset classes and industries.
MBBS, MD, MBA (NYU-Stern, Finance): worked/did research at Cornell and Harvard Affiliated Hospitals
Portfolio Manager/founder for own US biotech/pharma-focused asset management firm, Vasuda Capital Management (vasudacapitalmanagement.com).
Founder/Editor: Vasuda Healthcare Analytics: SA Marketplace premium biotech/pharma research service
Founder and Sponsor: Vasuda Global Orphan/Rare Diseases Index, first global equity index representing the orphan/rare disease sector (vasudaindices.com), index calculator=Solactive A.G. https://www.vasudaindices.com
I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com
You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (60,043) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options. I am not afraid to find some biotech stocks to short either after results have proven a drug to be ineffective. Looking at both the negative and positive aspects of biotech investing is the best way to invest in this sector.
I'm a former hedge fund and Goldman Sachs' research analyst who worked on the buy & sell-sides for more than a decade. Before investing professionally I was a strategy consultant at Bain & Co. I left Goldman to invest my own capital and explore several independent ventures - one of which is to create content that helps others to invest their own capital.
To that end, in May I'm starting a marketplace service called Cogent Alpha. I will fully disclose my own investments and explain why I've made them. Please follow me for more updates as I launch and build this service.
And then, outside of work...I'm from New Zealand and I've lived in many places, including Australia, the UK, the US and Hong Kong. My wife & I split our time between Hong Kong & Seattle. On the education front, I have an MBA from INSEAD and undergraduate degrees in Finance and Law from The University of Auckland.
My name's Adem Tumerkan - I'm 26 years old. Born contrarian and skeptic. I like the mining sector but I look for macro situations and asymmetric opportunities wherever they are.
My biggest influences are Mark Spitznagel and Nassim Taleb and Ben Graham. Those kind of guys.
Editor-in-Chief of www.Palisade-Research.com |
A Team of Contrarians and Experienced Investors Writing About Macro-Situations, Mining Stocks and Providing Top Market Research on Commodity Trends and Sector Cycles for our Readers. Most importantly, Turning Theory into Actual Practical Advice...
"Just find what you love, and let it kill you. . . " - C. Bukowski
Christopher Yuen is an investor, business owner and entrepreneur. He has over a decade of experience trading and investing in the U.S. Stock market. Christopher is also an entrepreneur, operating multiple businesses. He operates a full-scale vending machine business and is also an internet entrepreneur owning and operating several web properties.
Founder of Albright Investment Group, MBA graduate, active investor, and entrepreneur. I have a B.S. in management, and an MBA with a specialization in finance from top tier universities. I've been investing since 2002, and I enjoy writing about companies and topics that interest me. I manage a private long equity and ETF fund, and a secondary hedging/trading portfolio. I also host a very successful research service on Seeking Alpha, Albright Investment Group.
I am an experienced individual investor who has been trading merger arbitrage stocks and options since the 90's. I am a writer with a Master of Science from Northwestern University and I truly enjoy writing articles about the stock market. I try to look for opportunities where the odds are in my favor and there is a definite edge. On Seeking Alpha my articles will aim to provide insight and favorable risk/reward for the readers.However, I am not an investment advisor so any recomendations or ideas I write about in my articles, blogs, or comments shouldn't be taken as investment advice. I recommend using my writings as a starting point to which you should add your own research or that of an investment advisor.
"Any time you make a bet with the best of it, where the odds are in your favor, you have earned something on that bet, whether you actually win or lose the bet. By the same token, when you make a bet with the worst of it, where the odds are not in your favor, you have lost something, whether you actually win or lose the bet."
-David Sklansky, "The Theory of Poker"
At no point consider me an expert in anything. Science background, stints at various universities, the last being famous for economics, led to a career in the financial markets with postings around the world. 25 years of market experience does not make me an expert, it makes me a sanguine cynic towards beliefs peddled by others for their own benefit. I rather believe in building up one's own framework of economic, trading and personal values from first principles and experiences. Don't trust anyone trying to sell you a story, least of all me.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
"I usually ignore advice from other traders, especially the ones who believe they are on to a “sure thing”. The old timers, who talk about 'maybe there is a chance of so and so,' are often right and early. - Ed Seykota
- Disclosure: I am not a financial adviser. All articles are my opinion - they are not suggestions to buy or sell any securities. Perform your own due diligence and consult a financial professional before trading.
We are an independent Financial Education and Discretionary analysis blog, focusing on macro based instruments such as the Foreign Exchange markets, Stock Indices & ETFs. We aim to help users in their broad macro market analysis as well as refine their potential entry positioning by looking for high probability trading setups through our trading updates, which we hope will help participants generate market returns that are non-correlated to the stock market.
Visit us at: www.themarketmaster.com
I have nearly two decades experience in M&A, distressed debt, special situations and corporate lending both in the USA and in Western Europe, working for hedge funds, investment banks and commercial banks.
In 2008 I became interested in technical analysis primarily Elliotwave and trading foreign currencies.
I manage my own funds and that of a handful of other individuals with AUM totaling $3.5m.
I write articles on securities where I either hold a long or short position. Generally, if I do not have or want to have a position in a security then I will not write an article on such security. I am an investor first and a writer second. I try publish my articles simultaneously when opening or closing a position.
I am a dividend investor and look for undervalued investments in the stock market. I identify misunderstood and undervalued equity investments and hold those securities until their price approximates my estimate of intrinsic value. I am a long-term investor only.
I am building a $100,000 high-yield income portfolio. I am running this portfolio as an experiment to see if long-term sustainable income can be generated from a diversified pool of high-risk, high-yield securities. I am willing to accept high risk in order to meet my performance goals.
Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha. It is the fourth most subscribed to investment service offered through the Marketplace on SeekingAlpha.com. Our service offers a model-20 stock portfolio as well as the most active Live Chat on the Marketplace. This is where scores of seasoned biotech investors trade news and investment ideas back and forth throughout the trading day.
• • •
Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.
• • •
Learn more about Bret Jensen's Marketplace Offerings:
The Insiders Forum | The Biotech Forum | Busted IPO Forum
At Activist Stocks we use hedge funds and activist investors to find actionable investing ideas. That is, stocks with catalysts to unlock and generate shareholder value. Activist Stocks also offers a catalyst and event-driven idea forum for investors looking for unique idea generation, Catalyst-Driven Small-Caps, where I share daily activist and turnaround insights and deep dives.
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science.
Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity.
Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering.
With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.
Independent investor and stock analyst at Matrixtrade.com. Trend follower and market timer. Correlations and analogues. All time frames, all instruments.....wherever I see an edge I trade it.
Uncovering select special situation stocks.
California Real Estate Broker
CEO and President of Gibralter Financial and Real Estate Services from 2001 to 2008.
CEO of All Valley Mortgage 1993-1995
Private investor, Author and trader from 1999 to present.
Holmes Osborne is the principal of Osborne Global Investments. Holmes holds the Chartered Financial Analyst designation and a degree in finance from Syracuse University. He has been featured in the Wall Street Journal, Fortune Magazine, and Investors' Business Daily. Holmes has written financial columns for Seeking Alpha, the Motley Fool, theStreet.com, Gurufous, and several other publications. Osborne Global focuses on fixed income, value investing, and international stocks. Holmes is the father to two daughters, Adelaide and Emily.